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ABSTRACT
Background: The most frequent primary ocular malignancy in the western world is the uveal melanoma. While 
it mainly affects Caucasians, it is extremely uncommon among non-Caucasians. Continuous improvement in 
therapies for local treatment has allowed sparing of the eye, although this approach apparently does not improve 
survival. The present review aimed to explain different radiotherapy (RT) methods and compare the pros and 
cons of each method, along with the main complications that may be encountered in the treatment of uveal 
melanoma.
Methods: Relevant papers published between September 2009 and January 2021 were retrieved, reviewed, and 
screened. Four databases, including PubMed, MEDLINE, Google Scholar, and GeneCards, were searched for 
this purpose. 
Results: Forty-one relevant articles were identified. Based on the selected papers, we highlighted the advantages 
and disadvantages of the different RT methods that have allowed sparing of the eye, even though they have not, 
as yet, improved survival. We listed a detailed comparison between therapies that allow an educated choice 
among the different available RT methods. 
Conclusion: The choice of uveal melanoma management is determined by the location of the tumor and volume 
of the extraocular extent. At present, there is no gold standard for the management of all ocular melanomas, and 
each case should be approached individually. Therefore, classification is a valuable prognostic tool. Many cases 
in cT3-4 classification categories are treated by primary enucleation and conservative treatment follow-up, while 
in cT2 and most cT1 classifications (i.e., 3.1–6.0-mm tumor thickness), several forms of RT are used.
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INTRODUCTION
Melanoma is a malignant tumor associated with melanocytes, rarely associated with the eyes and tissues 
surrounding the eye (5%), even rarer is melanoma of mucosal origin (1%). An additional 2.2% of melanomas 
have unknown primary sites [1-3]. The uvea (85%), eyelid/orbit (10%), and conjunctiva (5%) are the most 
frequent tissues in which ophthalmic melanomas arise [2, 4, 5]. 
Uveal melanoma (UM) is the most common primary ocular malignancy [4, 6-11]. The incidence of UM in the 
western world is approximately 6 per million population per year [12]. The worldwide occurrence is estimated to 
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be between 4 and 7 cases per million people per year [4, 6, 7, 11, 13-20]. It primarily affects Caucasians, whereas 
it is very uncommon among non-Caucasians [17, 21]. UM most commonly affects adults aged 50–80 years, 
without a sex bias. It is predominantly unilateral [17] with bilateral choroidal melanomas (CMs) occurring in 
only 1 in every 50 million Caucasians [19]. 
The incidence of UM is estimated to be 1.3‒8.6 cases/million people, and CM is the most frequent primary 
intraocular malignancy in the western world [22, 23]. In contrast, it is approximately 20 times less frequent in 
Asia, where the reported incidence is about 0.25 cases/million individuals/year [22]. African American and 
Hispanic populations are less prone to developing UM than Europeans, while Chinese individuals are apparently 
affected at younger ages than westerners [13]. In Europe, the incidence of malignant UM is estimated to be 3‒5 
cases/100,000 individuals/year in Mediterranean countries [18, 24]. 
Individuals with congenital ocular or oculodermal melanocytosis (nevus of Ota) and uveal nevus are 
predisposed to melanomas, and particularly CM. In addition, somatic mutations in GNAQ, PTEN, and GNA11 
are found in > 50% of CM patients [20]. The continuous improvement of local treatments has allowed sparing of 
the eye, although this approach apparently does not improve survival. The present review aimed to compare the 
pros and cons of different radiotherapy (RT) methods, as well as the main complications that can be encountered 
in their application in the treatment of OM.
METHODS
Relevant papers , published between September 2009 and January 2021, were retrieved by searching the PubMed, 
MEDLINE, Google Scholar, and GeneCards databases. “Melanoma,” “radiation therapy,” “brachytherapy,” 
“choroidal melanoma,” “proton beam therapy,” and “classification” were the keyword combinations used. The 
identified papers were screened and appropriate papers were selected for inclusion in the review. 
RESULTS
Forty-one articles compatible with the aim of the current review were selected, and we focused on the most 
recent publications. Based on the 41 reviewed papers, we highlighted the advantages and disadvantages of the 
different RTs that have allowed sparing of the eye, even though they have not, as yet, improved survival in patients 
with OM. Table 1 lists the studies included in the present review, highlighting the key findings of each study. 
A summary of the main RTs used in the last decade for the management of UM is presented. Several factors 
were considered for the selection of the appropriate method, including tumor size, histopathological and genetic 
characteristics, tumor location (particularly when it is anterior), and presentation with extraocular extension 
(EOE) at the first examination [25]. We compiled a detailed comparison between therapies that allow an 
educated choice among the different available RT methods. In addition, Table 2 refers to the main RTs reported 
in the text and focuses on the advantages, disadvantages, and complications that are triggered by each method. 
Table 1. Details of studies included in the current review
Author (Year of Publication) Type of Study Key findings
Romanowska-Dixon et al. 
(2012) [1]
Cross-sectional study Following PBT, tumor thickness was 3.17 mm (1.5‒9.3 mm). PBT achieves local 
control in high rates.
Dunavoelgyi et al. (2013) [2] Cohort study (prospec-
tive observational)
Hypofractionated SRT achieved high efficiency in CMs when used at a dose of 
50 Gy in 5 fractions.
Kawczyk-Krupka et al. (2013) 
[3]
Review PDT may be a promising management, as many studies report the regression of 
cutaneous and CM.
Al-Wassia et al. (2011) [4] Retrospective case se-
ries
SRT using 60 Gy in 10 fractions is an effective and safe management.
Verma et al. (2016) [5] Systematic review PBT appears effective as it preserves visual acuity and provide high survival out-
comes
Dunavoelgyi et al. (2011) [6] Cohort study (prospec-
tive observational)
SRT achieves effective local tumor control and has comparable results to PBT.
Macdonald et al. (2011) [7] Retrospective case se-
ries
PBT is a suitable eye-preserving melanoma management used mainly in medium 
and large UMs.
Reynolds et al. (2016) [8] Letter to the editor Carbon fiducials for assistance with Gamma Knife radiosurgery treatment may 
be helpful when UM cannot be visualized on magnetic resonance imaging.
Somani et al. (2009) [9] Retrospective case se-
ries
SRT is a noninvasive alternative treatment for CM, with acceptable rates of ocular 
toxicity.
Haji Mohd Yasin et al. (2016) 
[10]
Retrospective study SRT provides local control and eye retention. Intravitreal injection of bevacizum-
ab seems not to decrease the rate of radiation retinopathy.
Bensoussan et al. (2016) [11] Retrospective, consec-
utive cohort study
PBT results in high rates of local control, without deterioration of survival. It may 
be used as an alternative approach in large CMs.
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Jager et al. (2020) [12] Review The understanding of tumor immunology and metabolism may lead to better 
control and achieve new, more effective treatments.
Tsai et al. (2018) [13] Case report GK-SRS can be utilized as a brief single-fraction treatment. 
De Caluwé et al. (2018) [14] Retrospective study A Dmin of 65 Gy in the management of the CM is needed to achieve a response. 
Mitsch et al. (2018) [15] Original article The regression rate appears to be non-linear , in contrast to very rapid or slow 
early tumor responses after treatment of CM with LINAC SFRT.
Fabian et al. (2018) [16] Retrospective analysis After treatment with 3 sessions of PDT, 62% of cases with posterior pole cT1a 
CM showed tumor regression in 27 months. Better response was reported in cas-
es with ≤ 3 risk factors.
Rundle (2017) [17] Review The use of PDT remains controversial in ocular oncology. However, with ap-
propriate case selection it may provide acceptable local control rates and visual 
acuity. 
Mosci et al. (2014) [18] Original article In the post-PBT follow-up of UM, internal reflectivity seems to be a better indica-
tor of early response when it is used in large tumors.
Mustafi et al. (2017) [19] Case report It is important to monitor patients with CM, particularly when choroidal nevi 
are present. 
Sas-Korczyńska et al. (2014) 
[20]
Original article PBT achieves good results when used in CM. The rate of eye preservation was 
93% and vision was protected in 80% of patients.
Weber et al. (2015) [21] Cohort study (prospec-
tive observational)
PBT provides acceptable survival rates and tumor control when used in large and 
anteriorly located melanomas. Vision function was acceptable and toxicity rates 
requiring enucleation were low.
Kim et al. (2018) [22] Retrospective analysis The results of PBT for CM were comparable with previous reports. Significant 
volume regression was reported after PBT.
Tran et al. (2012) [23] Retrospective analysis Excellent local control and toxicity rates were reported after PBT. T3 tumors ap-
pear to have higher rates of metastases and recurrence.
Virgili et al. (2007) [24] Incidence analysis/ 
case-control study
The incidence rate of UMs between 1983 and 1994 was reported to be stable.
Seibel et al. (2018) [25] Retrospective case se-
ries
PBT appears to present acceptable results when used in extraocular extension 
melanoma.
Gianniou et al. (2017) [26] Case report Calcified UM should be included in the differential diagnosis of cases with an 
atypical calcified and non-pigmented mass.
Fabian et al. (2017) [27] Prospective analysis PDT is an efficient treatment with a tumor control rate of 80%.
Schonfeld et al. (2014) [28] Retrospective analysis PBT provides efficient management in mid-zone CMs. However, consecutive 
treatment is frequently required.
Turkoglu et al. (2019) [29] Retrospective analysis PDT as a primary treatment achieved complete regression of the small amelanot-
ic CM over 5 years in 67% of cases.
Sellam et al. (2017) [30] Retrospective case-con-
trol study
Using optical coherence tomography angiography in patients with CM who were 
treated with PBT, both inner and outer plexus layers of choroid revealed changes, 
along with vascular rarefaction of the choriocapillaries. 
Krema et al. (2009) [31] Retrospective case se-
ries
SRT shows high efficacy, but enhances long-term ocular complications.
Chojniak et al. (2011) [32] Prospective nonran-
domized study
TTT is effective for the management of CM. However, subfoveal and perifoveal 
tumors show an early decrease in visual acuity.
Hartsell et al. (2016) [33] Prospective study High local control rates and low enucleation risk rates were reported using 3D 
treatment planning for proton therapy of CMs.
Riechardt et al. (2014) [34] Clinical case series, ret-
rospective study
Radiation-induced optic neuropathy may be present in several cases, but useful 
vision may be preserved at an acceptable rate.
Phillips et al. (2013) [35] Retrospective case se-
ries
A 3D conformal radiotherapy technique was efficient in the management of CM.
Russo et al. (2015) [36] Prospective case series Ultrasound and particularly magnetic resonance imaging could be used in the 
follow-up after PBT.
Campbell et al. (2012) [37] Case series Short-term efficacy of PDT for amelanotic CM is high, without vision impair-
ments, although the long-term effectiveness is uncertain.
Yan et al. (2018) [38] Research article A novel focused kV X-ray technique with potential NP protects healthy tissues 
while providing flexibility for management planning in patients with ocular mel-
anoma.
Dunavoelgyi et al. (2012) [39] Retrospective study Hypofractionated SRT and PBT present comparable rates of long-term side ef-
fects (low to moderate) when used for central CM.
Konstantinidis et al. (2015) 
[40]
Retrospective study PBT avoids upper eyelid margin damage and complications. Additionally, local 
tumor control remains stable.




Toxic tumor syndrome (the persistence of the irradiated eye tumor within the 
eye) after PBT of a CM provokes complications, such as neovascular glaucoma 
and exudative retinal detachment.
Abbreviations: 3D-CRT, 3-dimensional conformal radiotherapy; UM, uveal melanoma; CM, choroidal melanoma; Dmin, minimum dose 
to the tumor; GK-SRS, Gamma Knife Perfexion® stereotactic radiosurgery; kV, kilovolt; LINAC, linear accelerator; NP, nanoparticle; PBT, 
Proton beam radiotherapy; SFRT, stereotactic fractionated radiotherapy; SRT, stereotactic radiotherapy; PDT, photodynamic therapy; TTT, 
transpupillary thermotherapy.
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Table 2. Evidence based advantages, disadvantages, and complications of the main RTs
Radiation Therapy Advantages Disadvantages/Complications
RT Modalities Privileged treatment in medium-sized and symptomatic, 
small CMs [35]. RT uses X-rays, whereby high-kinetic 
energy electrons are directed at deep seated tumors [38]. 
A focused kV beam X-ray technique causes significantly 
less damage in critical structures of the eye than PB, costs 
less, and does not involve surgery [38]. 
X-rays used are non-directional and not focusable. 
Thus, RT lacks precision and therefore puts organs 
(non-targeted but near the tumor) at risk of being 
damaged, even if synchrotron-based beams are used 
[38]. 
Poor visual outcomes in juxtapupillary lesions [4].
External Beam Therapy In the case of UM, proton and helium-ion RT achieve > 
90% local tumor control [6].
In 5% of cases, recurrent tumor growth was detected 
with a median follow-up of 53.2 months. Among 39 
enucleated eyes, the 2 most common causes of enu-
cleation were NVG and recurrent tumor growth, in 
25 and 8 cases, respectively [6].
CPT Promising results have been reported in the treatment 
of juxtapupillary tumors [14, 35]. Low local failure rates 
have been reported (4.21%); SRT had rates of 6.20% and 
PB 9.45% [10].
CPT has the drawback of greater neutron tissue ex-
posure, as compared with essentially no exposure 
when using photons [14, 35].
PBT PBT is applicable in a wider range of tumors (both poste-
rior peripapillary tumors and anteriorly located tumors) 
[4, 20, 21, 23, 33, 40]. Twenty percent of ocular melano-
mas are treated with PBT [20]. Local control rates of over 
90%, sustained for 10 years [5, 20, 23] were achieved. It is 
suitable for cases where brachytherapy is not advised, in-
cluding large tumors or cases with extrascleral extension 
[21]. It reduces metastasis rates [11] and the potential 
need for enucleation as compared with brachytherapy 
[20]. It is superior in maintaining healthy tissue [2] and 
has good eye retention rates [11]. 
It offers a low visual acuity prognosis and rate of eye 
conservation for large melanomas [2]. It has more 
anterior segment complications [11]. Irradiating 
large volumes with exceedingly high doses increase 
complications rates, resulting in secondary enucle-
ation [7, 11]. Although most tumors shrink, they 
do not disappear after irradiation [18]. The ocular 
recurrence-free rate for nonperipapillary melanoma 
is approximately 85% at 5-years, which is lower than 
the 90–97% rate for medium-sized tumors [21].
Complications: retinopathies (23‒67%), cataract 
(20‒62%), glaucoma (7‒30%), optic neuropathy 
(7‒33%), and vitreous bleeding (9‒14%) [5]. Rubeo-
sis iridis and NVG after PBT may lead to enucleation 
[7, 22, 28]. Microvasculopathy may ensue [30].
SRT Management of juxtapapillary CM by delivering an ade-
quate dose, independently of tumor location in relation 
to the optic disc [35, 39]. Noninvasive methods, such 
as MRI and CT, can determine the tumor’s location and 
borders [2, 31]. No preoperative surgical marking is nec-
essary. SRT is more cost-effective [2]. It seems to be su-
perior to GK radiosurgery because it utilizes a relocatable 
immobilization frame and thus delivers irradiation in 
multiple fractions [6]. Surgical insertion of localization 
clips in melanomas patients seems to be another SRT 
advantage [22]. The SRT tumor control rate has been 
reported as 94% at 37 months, which is comparable with 
the 85% 5-year rate for brachytherapy of juxtapapillary 
melanoma or the 83% rate for helium-ion RT [31]. 
The delineation of the extent (borders) of the tumor 
based only on CT images is challenging [22]. Radia-
tion retinopathy may ensue [10].
GK Radiosurgery GK irradiation employs a fixed immobilization frame 
that is anchored to the skull to ensure akinesia during the 
single-dose radiosurgery [6, 31].
It seems to be inferior to SRT [6, 31].
PB PB apparently provides equivalent survival rates to PBT 
[7, 20]. It is less expensive and time-consuming than 
PBT [20]. It is the preferred eyeball-preserving treat-
ment for CM [22].
Local control of posterior tumors by PB is inferior to 
that achieved with PBT. This is attributed to impre-
cise position of the plaque (particularly at the pos-
terior pole) and suboptimal immobilization of the 
plaque [5, 11].
TTT TTT, compared with plaque radiotherapy, results in rapid 
tumor regression. TTT has less severe and diffuse side-ef-
fects and complications. It is effective in selected small 
CMs [32].
Visual acuity is reduced, and is detected early after 
treatment or mainly concomitant with treatment, 
and complications of subfoveal and perifoveal tu-
mors. Complications, in order of frequency, are ret-
inal vascular occlusion, papillopathy, retinal traction, 
retinal detachment, vitreous hemorrhage, and mac-
ulopathy [32].
PDT Good tumor control rates in pigmented and non-pig-
mented CMs [16].
High recurrence rate, even in small CMs [16].
Abbreviations: CM, choroidal melanoma; CPT, charged particle treatment; CT, computed tomography; GK, Gamma Knife; kV, kilovolt; 
MRI, magnetic resonance imaging; NP, nanoparticles; NVG, neovascular glaucoma; PB, plaque brachytherapy; PBT, proton beam therapy; 
PDT, photodynamic therapy; RT, radiotherapy; SRT, stereotactic radiotherapy; TTT, transpupillary thermotherapy; UM, uveal melanoma.
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DISCUSSION
Melanoma mostly metastasizes either by local spreading or by hematogenic dissemination [7, 10] with between 
2.3% and 5.5% of the patients presenting with EOE at the first examination. Poor survival is associated with larger 
tumors and anterior tumor extension, diffuse melanoma, and genetic and histopathologic characteristics, such 
as epithelioid cell type, which are also associated with EOE [25]. Almost 50% of patients show simultaneous 
metastasis at the initial diagnosis [15], which is responsible for the death of nearly 50% of UM cases [17]. The 
principal site of metastasis is the liver [2]. 
The location and volume of the EOE determine the choice of treatment. Most patients present with anterior 
EOE. When EOE appears posteriorly, enucleation is the most frequently used technique. Therefore, there are 
fewer than 50 reports in the literature regarding the implementation of primary irradiation in patients with 
posterior EOE. In these cases, local recurrence rates are reported to be equally low, irrespective of whether plaque 
radiotherapy (PR) or proton beam therapy (PBT) are used for treatment [25]. It is important to note that EOE 
is not associated with loss of local tumor control, and it is not a marginal factor in local failure of PBT. However, 
EOE with a tumor diameter > 5 mm is associated with loss of local tumor control and is a marginal factor in local 
failure of PBT. It is also an additional risk factor for metastasis and vortex vein invasion. Optic nerve infiltration 
occurs in 5.7% of UM cases. However, optic nerve invasion is reported to occur in approximately 34% of patients 
with no funduscopically identifiable juxtapapillary tumor growth [25, 26]. 
Depending on the irradiation modality used for treatment, the outcome depends on tumor size, plaque size, 
radiation dose, and the amount of tissue damaged by radiation [27]. Visual prognosis also depends on the tumor 
position relative to the fovea and optic disc [22]. The introduction of better therapies, which have been successful 
in local treatment during the last 3 decades, has allowed sparing of the eye in many cases, although it is debatable 
whether they have improved survival [2]. 
Given that the prognosis of metastatic disease is poor [7, 10], decisions regarding small tumors should be 
based on the presence of indications of malignant transformation and the inherent risks of treatment [2]. The 
most notable predictive factors for melanoma-associated mortality are the associated genetic alterations [15], 
while age, initial tumor dimensions, tumor location, and epithelioid cell type are risk factors for metastasis 
[2, 15, 23]. Tumor diameter at presentation (> 10 mm), male sex, and age (> 60 years) are the most reliable 
predictive factors for metastatic disease [28]. Perimacular and peripapillary melanomas have a higher risk of 
local recurrence [6]. The 5-year survival rate of UM is estimated to be between 69% and 82% [10]. Tumors 
anterior to the equator that invade the ciliary body have a very poor prognosis. Tumors posterior to the equator 
that invade the optic nerve or the macula region exhibit a better prognosis. Tumors of the anterior aspects of the 
eye may be difficult to detect and may be asymptomatic and often present at more advanced stages [21]. 
UMs are classified by the American Joint Committee on Cancer (AJCC) based on a number of variables, 
including tumor size, tumor localization, and whether or not they present with EOE. The AJCC classification 
is a valuable prognostic tool. CM, classified by the AJCC as cT3-4, is treated by primary enucleation with 
conservative treatments, with variable results. For cT2 and cT1 classifications (i.e., 3.1–6.0-mm tumor thickness), 
local RT, PR, or PBT are used. For cT1a tumors, which present with thickness ≤ 3 mm, or those cases that 
may be characterized as “borderline” (i.e., suspicious nevi), opinions differ. Many investigators have proposed 
early treatment of these tumors with local RT, with the aim of reducing the possibility of adverse mutations 
and lowering the metastatic risk. Others prefer not to treat small lesions in asymptomatic patients, provided 
that there is no evident tumor growth, to avoid the deterioration of vision that is the result of RT in > 50% of 
cases [16]. There is no universal agreement on the optimal treatment option for patients presenting with T3 
tumors; however, cautious investigators suggest that the upfront enucleation option must be followed. There are 
a number of alternative options available to patients with T3 tumors who wish to avoid upfront enucleation. One 
of these is dose escalation, which aims to achieve better tumor control, coupled with intravitreal bevacizumab 
to address the problem of increased toxicity (from higher doses) to normal ocular structures. A second option 
is the combination of hyperthermia and proton therapy. Hyperthermia is a known radiation sensitizer, and thus, 
a means of improving local control. The third alternative strategy is to address marginal failures better through 
more accurate modeling of the tumor [23]. High-risk patients could be candidates for combined treatment, such 
as systemic therapy with targeted agents and enucleation [21].
There are 2 main strategies for treating UM patients with no systemic metastasis, including eye-conserving 
therapies and enucleation [2]. Of these, RT techniques (which have a better than 90% success rate), including 
PBT, gamma-knife (GK) radiosurgery, plaque brachytherapy (PB), and transpupillary thermotherapy (TTT), as 
well as photodynamic therapy (PDT) are the most promising eye-preserving treatments for UM. However, they 
are not free of complications, including papillopathy and radiation maculopathy [14, 15, 29, 30]. 
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Tumor size and intraocular location are thought to be the primary determinants of treatment modality choice 
[4, 6, 20, 21]. Although enucleation is unavoidable in some patients, given the large tumor size at the initial 
diagnosis, eye-preserving approaches are equally successful in terms of both survival and metastasis-free survival 
[6]. There is also an ever-increasing trend for early treatment (instead of more conservative monitoring) of small 
melanomas [2]. In the case of juxtapupillary CMs, there is no clearly and universally accepted management 
strategy. Several management strategies have been proposed, including enucleation, endoresection, charged 
particle RT, notched PR, and external beam stereotactic radiotherapy (SRT) or stereotactic radiosurgery (SRS) 
[9, 31]. In juxtapupillary CMs, the management focuses first on local tumor control and on the prevention of 
metastases and death [7, 32] and, secondarily, on eye retention, both for functional and cosmetic reasons [7]. 
When comparing the present state-of-the-art treatments, radiation (SRT, charged particle RT and PB) versus GK 
radiosurgery and laser TTT provide superior local tumor control, with mean failure rates of 19%, 21%, and 6%, 
respectively [10, 42]. 
In addition to surgery, laser therapy, and chemotherapy, RT is considered one of the most successful methods 
for the treatment of OM. Similar to all radiation treatments, in the case of OM, cancer cells are destroyed mainly 
by high-energy X-rays. External-beam RT is the most frequently used type of RT. This is in contrast to radiation 
treatments that are delivered using implants, that is, internal radiation therapy, also called brachytherapy, or 
plaque therapy. Finally, proton therapy is an external-beam radiation therapy that destroys cancer cells by using 
high-energy protons [4-6, 20].
The Collaborative Ocular Melanoma Study (COMS) was initiated with the express purpose of (a) determining 
whether patients with medium-sized CM showed prolonged survival with enucleation or brachytherapy, and (b) 
assessing whether preoperative radiation in patients with large CM have prolonged survival after enucleation 
[14, 17, 22]. The COMS results showed that patients with medium-sized CM did not have significantly different 
mortality rates at 12 years, irrespective of whether they were treated with PB or were subjected to enucleation. 
The apparent equivalence of treatments resulted in the exploration of episcleral PB, proton-beam treatment, 
and SRT as eye-preserving treatments [2, 7, 11, 14, 15, 21-23, 29, 31, 34, 35]. Following COMS, medium-sized 
or smaller CMs are treated mainly with brachytherapy [14, 22] while tumor control has been associated with a 
minimum dose to the tumor (Dmin) of 85 Gy delivered to the apex of the tumor as the gold standard [14].
In the small melanoma arm of the COMS, the estimated mortality related to melanoma was 1% at 5 years 
and approximately 3.7% at 8 years [2]. However, the COMS excluded large melanomas. In the case of large 
melanomas, enucleation, either alone or following external beam therapy, was applied, but no difference in 
survival at 10 years was observed between the 2 treatments [2, 11]. Multivariable analysis of the COMS data 
identified that tumor height was a significant predictor of local failure, along with the location of the tumor, as 
juxtapupillary tumors presented a higher probability of local failure [14]. 
As in every case of collaborative studies, the accuracy of diagnosis of the condition is of cardinal importance. 
In this respect, the results of the COMS had a significant impact, given that the COMS reported a misdiagnosis 
rate of only 0.4 % [17, 36]. Of course, as in all similar studies, the COMS had its own limitations. Patients with 
peripapillary tumors appear to have a high rate of recurrence and metastases; thus, the COMS excluded these 
patients [23]. Apart from its limitations, however, the COMS has clearly influenced the evolution of RT during 
the last 20 years. 
Radiotherapy Modalities
RT encompasses 3 treatment approaches: stereotactic fractionated radiotherapy (SFRT), PB, and charged 
particle RT (CPRT), which uses protons or helium-ions [4, 7, 10, 13-15, 17, 27, 28, 37]. Variations of these 3 
treatment modalities are SRT and CPRT (which, in the case of OM, mainly refers to PBT), linear accelerator 
(LINAC)-based SFRT, and GK radiosurgery [13-15, 17]. Today, RT has become the treatment of choice for 
medium-sized and symptomatic small CMs [35].
RT uses X-rays, whereby high kinetic energy electrons (millions of electron volts or MVs) in the form of X-ray 
beams are directed at deep-seated tumors. The problem associated with this is the scattering of X-ray beams. Even 
when using synchrotron-based beams, which are focused and have scatter directed in the forward direction, RT 
lacks precision and therefore puts non-targeted organs near the tumor at risk of being damaged [38].
A focused kilovolt (kV) beam X-ray technique causes significantly less damage to critical structures of the eye 
than PB, costs less, and does not involve surgery. However, its principal disadvantage is that it delivers smaller 
doses to deep structures than MV beams. The solution to this problem of low dose is to use nanoparticles (NPs) 
with a high atomic number (Z). These NPs enhance the effect of kV X-rays to a point that is substantially more 
effective than MV beams, thereby achieving the desired therapeutic dose-concentration within the tumor [38]. 
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Thus, NPs, which are non-toxic and are eliminated by renal clearance, are used to target the tumor precisely. 
To do this end, the method takes advantage of the enhanced permeability and retention effect and uses NPs 
that are attached to antibodies directed at tumor-specific antigens. Because the photoelectrons and the NP-
emitted Auger cascade electrons appear in short ranges, they are more effective than radiation alone, because 
they damage only cells within the tumor boundaries. Thus, radiosensitization by NPs, whether in the kV or MV 
ranges, is much greater than other physical dose-enhancement methods. In the case of melanoma, the kV X-ray 
technique combined with eye immobilization and localization techniques results in ≤ 1.0 mm uncertainty, which 
is of particular importance in the treatment of CMs [38]. 
External Beam Therapy
Charged particle therapy along with GK and LINAC-based SRS are termed “external beam therapy techniques” 
[2, 39]. 
Charged Particle Treatment 
Charged particles, such as protons, are used for therapeutic irradiation in charged particle treatment (CPT). 
Treatment is delivered either by using a LINAC for photon therapy (i.e., high-energy light), or by protons and 
other cyclotron-generated charged particles. Charged particles and photon irradiation differ in that the first 
provokes a smaller exit dose through normal tissue as they stop abruptly in the tissue (Bragg peak; a peak on the 
plot of the energy loss of ionizing radiation beam versus the distance it travels through matter). CPT has yielded 
promising results in the treatment of juxtapupillary tumors [14, 35]. Indeed, this group of treatment modalities 
showed low local failure rates. Thus, CPT yielded a local failure rate of 4.21%, while SRT yielded a failure rate of 
6.20%, and PB had a failure rate of 9.45% [10].
Proton Beam Therapy 
Although PBT is associated with more anterior segment complications, recent evidence shows that it has good 
eye retention rates [11]. The planning of PBT treatment for CM must always consider the lens, anterior chamber, 
and ciliary body volumes [22]. PBT can achieve local control rates of over 90%, which are sustained for 10 
years [5, 20, 23]. Local control is improved by endoresection of the remaining part of the tumor [20] with 
a 5-year overall consistency within the 70%–85% range that is apparently, improving [5]. Large uveal tumors 
pose a particular challenge, because they are sometimes associated with increased local failure risk when 
treated conservatively [7, 11]. Death rates due to metastasis have not decreased despite the better local control 
achieved by the conservative treatment, which aimed to simultaneously control the tumor in the affected eye 
and maintain eye function completely as possible. [7]. Irradiating large volumes with exceedingly high doses 
increases complication rates, resulting in secondary enucleation [7, 11]. The increased risk of liver metastasis 
in these individuals is another concern, although there are reports based on murine models that PBT probably 
reduces metastasis rates [11]. It seems that enucleation is used more frequently in cases with ciliary body tumors, 
tumors with an anterior location, and tumors close to the optic disc or fovea. In addition, other factors that may 
increase the use of enucleation are the diameter and height of the tumor, dose of radiation, irradiation of the 
anterior segment, EOE, and ocular extension [7]. In histopathological terms, PBT causes necrosis, fibrosis, and 
balloon cells in the tumor tissue (i.e., PBT causes tumor degeneration), fewer mitoses, and damage to the tumor 
blood supply. However, although most tumors shrink, they do not disappear following irradiation [18]. Weber 
et al. found that the ocular recurrence-free rate is approximately 85% at 5-years for PBT in non-peripapillary 
UM, which was lower than the 90%–97% rate for medium-sized tumors. This is coupled with a metastasis-free 
survival rate of approximately 72% at 5 years, whereas the overall survival rate is almost 77%. Authors concluded 
that both of these are lower than the 80%‒90%, mostly reported in the literature [21]. 
In a study that validated the AJCC staging system, which registered 3,800 individuals with melanoma, an 85% 
metastasis-free survival rate at 5-years was reported for stage 2 (stage IIa + IIb) patients. In another study of 
non-peripapillary CM and melanoma of the ciliary body that was treated with PBT, all ocular recurrences were 
located anterior to the equator, without recurrences occurring in the 36 patients who presented with tumors that 
were located posteriorly [21]. In cases where the tumor was located in the posterior pole (near the macula and 
the optic disc), vision function deteriorated by 33%–47% within 12–24 months after proton radiotherapy, while 
similar deterioration was reported in only 17%–28% of cases with tumors in other locations [20]. The doses 
utilized in older studies ranged from 56 to 60 Gy relative biological effectiveness (RBE), in 4 fractions, and up to 
70 GyRBE, in 5 fractions [33]. However, no differences in local control and overall survival were noted at 5 years 
for a dose of 70 GyRBE (standard total dose) compared with those of a lower dose of 50 GyRBE, when both 
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treatments were delivered in 5 fractions over a span of 7‒10 days. Similar rates of maculopathy and papillopathy 
have been observed between the 2 groups [14, 33]. However, at 5 years, a smaller visual field loss was recorded 
in the group treated with a reduced dose [33].
Hypofractionated PBT treatments contribute to the cost-effectiveness of PBT compared with tumors that 
require conventional fractionation [5]. The non-inferiority of PBT for metastasis and tumor survival has been 
amply demonstrated [28]. A local control rate of up to 98.9% at 5 years has been recorded in large groups of PBT-
treated patients with iris, ciliary body, or CM, with a local recurrence rate of 6.1% at 5 years [40]. The reported 
3% retreatment rate was attributable to recurrent tumor growth [28]. The ocular retention rate at 10 years is 
reported to range from 86.2% to 95% [40]. 
Following PBT, the tumor size shrinks, while sonographic internal reflectivity becomes significantly enhanced. 
However, tumor regression occurs anywhere from 6 months to 2 years [36]. Most local recurrences were reported 
in the first 3 years after treatment, while there is a reported case of an eye that developed a second CM after 20 
years [19] following PBT for UM. 
Complications of PBT include retinopathies, cataracts, glaucoma, optic neuropathy, and vitreous bleeding 
[5]. Neovascular glaucoma (NVG) is a major complication and a frequent cause of enucleation [7, 22, 28]. 
The greatest risk for enucleation is attributable to complications of PBT, mainly NVG, rather than to tumor 
recurrence [33]. NVG correlates with the volume of treatment and the dose delivered to the anterior segment 
that is contained in the treated field (particularly the ciliary body and lens) [33, 41]. Scar endoresection and 
aqueous shunt placement [5] have been used after PBT to control post-PBT glaucoma. However, therapies 
such as laser, intravitreal injections, and surgical endoresection have rendered PBT complications manageable 
[11, 28]. Μicrovasculopathy, including capillary occlusion and/or incompetence, are the main characteristics 
of radiation retinopathy following PBT. The initial damage to endothelial cells of the retinal capillary causes 
loss of these cells and vessel occlusion, first in retinal capillaries, followed by that of larger vessels (Table 2) 
[30]. 
Stereotactic Radiotherapy
SRT is used in the management of juxtapapillary CM because the delivery of an adequate dose is independent 
of tumor location on the optic disc [35, 39]. A suction fixation method has been described that involves 
retrobulbar anesthesia, followed by fixation of the eye by a circular vacuum chamber attached to the stereotactic 
head frame. Before GK radiosurgery, retrobulbar anesthesia is also used. Recent developments in non-invasive 
immobilization systems include the use of a thermoplastic mold for the immobilization of both the head and 
eyes while patients are “gazing forward,” or by having the patients look at a fixation point using the melanoma-
affected eye, while being monitored by video, or having the patient look at a fixed point of light [35]. 
Although PBT seems to be superior in maintaining healthy tissue, Hypofractionated SRT has the advantage 
in certain cases, particularly because no preoperative surgical marking is necessary, and because it is more cost-
effective [2]. SRT utilizes a relocatable immobilization frame and can deliver irradiation in multiple fractions. On 
the other hand, GK irradiation employs a fixed immobilization frame anchored to the skull to ensure akinesia 
during single-dose radiosurgery [6, 31]. In cases of UM, LINAC-based SRT may be an alternative therapeutic 
option [6]. The advantages of SRT are summarized in Table 2.
There have been relatively few evaluations of the efficacy and complications of SRT in the treatment of UM 
with a sufficient follow-up time [31]. Radiation retinopathy (i.e., the appearance of clinically or angiographically 
confirmed retinal ischemic vasculopathy > 2 mm beyond the tumor margin, which may or may not involve the 
macula, and which is characterized by retinal hemorrhage, edema, infarcts, exudates, or neovascularization), may 
be present in 71%–88% of patients at ≥ 5 years after SRT treatment [10].
Comparison of treatment modalities 
Proton Beam Therapy versus Brachytherapy 
Particle beam therapy, when compared to brachytherapy, provides outcomes at least as good as those of PB [5, 
33]. In a prospective randomized study comparing helium particle beam therapy with brachytherapy in patients 
who received particle beam therapy showed better local control (100% versus 84% after 5 years and 98% versus 
79% after 12 years). The need for enucleation was higher after PB than after particle therapy (37% versus 17% at 
12 years). The analysis also identified that the management modality used may be the most significant factor for 
the prediction of eye preservation, local control, and disease-free survival [33, 43].
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Photon Beam Therapy versus Plaque Brachytherapy  
PB provides local control equivalent to that of PBT (over 90%) [5]. Local control of posterior tumors by PBT 
was superior to that achieved with PB. This is attributed to the imprecise position of the plaque (particularly at the 
posterior pole) and suboptimal immobilization of the plaque. For anterior tumors, these 2 treatments are apparently 
equivalent [5, 11]. Although better results for local control were obtained with PBT than with brachytherapy, survival 
rates were comparable [7, 20]. PBT is more expensive and time-consuming than brachytherapy, and although PBT 
reduces the potential need for enucleation (due to complications) by 47% compared with brachytherapy [20], PBT 
can be accompanied by important side effects affecting the ocular and extra-ocular structures [7]. Because of the 
greater vision impairment associated with PBT than with brachytherapy [20], plaque therapy using ruthenium-106, 
cobalt-60, and iodine-125 is the preferred eye-preserving treatment for CM, as it is associated with slightly higher 
local control rates than PBT [22].
Proton Beam Therapy versus Stereotactic Radiotherapy 
SRT and PBT have comparable local control outcomes when used in CMs [23]. Surgical insertion of localization 
clips in patients with melanomas seems to be an advantage of SRT. However, delineating the extent (borders) of 
the tumor based only on CT images, which is the method used in SRT, is challenging. Therefore, other techniques 
may complement CT, including digital fundus photography, MRI, or radiographic techniques using intravenous 
contrast agents. In addition, carbon-ion RT and PBT present comparable local control rates in cases of CM [22]. 
Furthermore, large studies have confirmed that both PBT and SRT provide local control in the order of 95%–97%. 
It should be noted that PDT differs from PBT and SRT in that it stabilizes or even improves the patient’s vision, 
while patients undergoing PBT or SRT can expect a visual loss of ≥ 3 lines on a Snellen chart in 45%–65% of cases 
[17].
Plaque Brachytherapy versus Stereotactic Radiotherapy 
No serious comparisons (e.g., randomized control trials) have been reported between SRT and PB in the treatment 
of CM. Moreover, no statistically significant differences have been reported between SRT and PB in terms of local 
control [10].
Transpupillary Thermotherapy versus Plaque Radiotherapy 
Compared with PR, TTT results in rapid tumor regression, and brachytherapy is associated with more severe and 
diffuse side effects and complications than TTT [32].
Photodynamic Therapy versus Transpupillary Thermotherapy and Photocoagulation
Efforts to introduce photocoagulation and TTT for small CMs have been abandoned because of the reported high 
recurrence rate. However, PDT applied in pigmented and non-pigmented CMs achieves good tumor control rates 
[16].
Hence, the outcomes of different irradiation regimens depend on several factors, including tumor size, plaque size, 
radiation dose, and the amount of tissue that is damaged by radiation [27]. Decisions regarding small tumors should 
be based on the presence of indications for malignant transformation and the inherent risks of treatment [2]. The 
AJCC classification is a valuable prognostic tool. Although in cT2 and in most cT1 classifications (i.e., 3.1–6.0-mm 
tumor thickness), local RT, PR, or PBT are used [16], there is no universal agreement on the optimal management 
option for patients with T3 tumors [23]. Many cases with cT3-4 tumors are treated by primary enucleation with 
conservative treatments, yielding variable results [16].
Therefore, UM treatment can follow 1 of 2 strategies: eye-conserving therapies or enucleation [2]. Despite their 
complications (i.e., papillopathy and radiation maculopathy) [14, 15, 29, 30], RT techniques (with > 90% success 
rate) seem to be more promising, including PBT, GK radiosurgery, and PB, along with TTT and PDT. Moreover, RT 
may be among the most successful methods used for the treatment of OM [4-6, 20]. 
The COMS results indicated that, irrespective of whether PB or enucleation was used, medium-sized CMs did 
not have significantly different mortality rates at 12 years. Thus, new eye-preserving treatments, including episcleral 
PB, PBT, and SRT, have been explored [2, 7, 11, 23, 29]. Following the COMS, medium-sized or smaller CMs 
have been managed mainly with brachytherapy [14, 22] which has become the treatment of choice in the case 
of medium-sized and symptomatic small CMs [35]. Following the COMS, medium-sized and smaller CMs are 
managed mainly with brachytherapy.
Compared to brachytherapy and SRT, proton therapy is applicable to a wider range of tumors and can be used in 
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the treatment of both posterior peripapillary tumors and anteriorly located tumors [4, 20, 21, 23, 33, 40]. Despite 
the fact that, theoretically, choroidal, ciliary body, and iris melanomas can be treated with PBT, the visual acuity 
prognosis and rates of eye conservation for large melanomas remain low [2]. PBT is particularly suited for cases 
where brachytherapy is not advised, including large tumors or cases with extrascleral extension [21]. The physical 
properties of PBT (i.e., beginning with a low dose, followed by an increased dose to the target as per the Bragg peak, 
and finally a rapid fall-off, distal to the target) makes PBT attractive for treating the eye [2, 4, 5, 20, 21, 28, 34, 40]. 
The present review focused on the most recent literature, published in the last decade, and deposited in 4 
widely used databases: PubMed, MEDLINE, Google Scholar, and GeneCards. It also highlights the most recent 
RT modalities used in the management of UMs. In addition, it refers to appropriate management approaches for 
melanomas of different classes. However, many of the articles found in the literature utilized different methodologies 
and described small samples with specific patient characteristics. Thus, the results may not necessarily apply to all 
UM patients. Moreover, it is difficult to compare the results of the treatments used for melanomas with different 
characteristics effectively. Future studies should aim to investigate the use of the most efficient method or 
combination of methods for the individual and to determine the most appropriate timing for the selected treatment 
to achieve better results. Furthermore, it is crucial to compare different types of management in patients with small-, 
medium-, or large-sized melanomas, or melanomas at specific locations, more thoroughly. In addition, robust study 
designs, such as randomized clinical trials, may be able to provide more reliable and applicable results.
CONCLUSIONS
Overall, OM may be treated with different strategies, depending on the tumor characteristics, including size, 
thickness, and location. At present, there is no gold standard for the management of all OMs, but each case should be 
approached individually to minimize ocular manifestations and extraocular metastasis, if possible. Further research 
is needed to explore the results of different treatment modalities in patients with metastatic or non-metastatic OM 
with different characteristics.
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